date:May 15, 2014
l further validate the health benefits of NR. We plan to add to that research by beginning our first clinical study on NIAGEN in the second quarter.
In January 2014, the company announced it entered into a four year ingredient supply and brand licensing agreement valued at approximately $62 million, with 5LINX. 5LINX was granted marketing rights for ChromaDex's patented NIAGEN nicotinamide riboside ingredient for use in dietary supplements exclusively in the network marketing sales channel in